|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.120 USD | +17.13% |
|
+23.98% | +42.28% |
| 11-14 | Marker Therapeutics Q3 net loss narrows to $2 mln | RE |
| 11-13 | Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
Evolution of the Average Target: Marker Therapeutics, Inc.
Evolution of the Target Price: Marker Therapeutics, Inc.
Changes in Analyst Recommendations: Marker Therapeutics, Inc.
163d26bd055803a20c005.dPAqTS6fYa75WTbR2miwg-QvwZKpFr6Wqd2dZFZJGWs.ILtEIELWOMCPI1vkqjvm94FI8aX_e4au_472KRkjd1JAp20MQPQH4LUIBg~f518146bf28f05a90a6f222b13c70640
More recommendations
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +271.07% | |||||
| +24.68% | |||||
| +11.11% | |||||
| +20.91% | |||||
| +13.89% | |||||
| -13.28% | |||||
| -9.4% | |||||
| Average | +45.57% | |||||
| Weighted average by Cap. | +12.22% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.120USD
Average target price
7.867USD
Spread / Average Target
+271.07%
High Price Target
10.00USD
Spread / Highest target
+371.70%
Low Price Target
5.600USD
Spread / Lowest Target
+164.15%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Canaccord Genuity | |
| Ladenburg Thalmann | |
| Piper Sandler | |
| Roth Capital Partners | |
| Oppenheimer | |
| Cantor Fitzgerald |
SellBuy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.120USD
Average target price
7.867USD
Spread / Average Target
+271.07%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRKR Stock
- Consensus Marker Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition